What is the appropriate levosalbutamol (levalbuterol) inhalation drop dosage for pediatric patients, including infants and children, based on age and weight?

Levosalbutamol (Levalbuterol) Nebulizer Dosing for Pediatric Patients

For pediatric patients with asthma, start with levosalbutamol 0.31 mg nebulized every 4-6 hours for children under 5 years, and 0.31-1.25 mg for children 5-11 years, with the option to increase to 0.63 mg in younger children or those with more severe disease.

Age-Specific Dosing Recommendations

Children Under 5 Years of Age

• Starting dose: 0.31 mg/3 mL nebulized solution 1
• Frequency: Every 4-6 hours as needed
• Important note: Levosalbutamol does not have FDA-approved labeling for children under 6 years, though clinical trial data supports its use 1

Children 5-11 Years of Age

• Dose range: 0.31-1.25 mg in 3 cc 1
• Frequency: Every 4-6 hours as needed
• For mild to moderate persistent asthma, start with 0.31 mg 2

Acute Exacerbations (All Pediatric Ages)

Weight-based dosing is preferred in acute settings:

• 0.075 mg/kg (minimum dose 1.25 mg) every 20 minutes for 3 doses 1
• Then 0.075-0.15 mg/kg every 1-4 hours as needed
• This represents half the milligram dose of racemic albuterol while providing comparable efficacy 1

Clinical Decision Algorithm

Step 1: Assess Disease Severity

• Mild-moderate persistent asthma → Start 0.31 mg
• Severe asthma or acute exacerbation → Use weight-based dosing (0.075 mg/kg, minimum 1.25 mg)

Step 2: Age Considerations

• Children <5 years: 0.31 mg is the safest starting dose with best cardiovascular profile 3
• Children 5-11 years with mild disease: 0.31 mg
• Children 5-11 years with severe disease: May benefit from 0.63 mg or higher 2

Step 3: Monitor Response

• If inadequate response after 0.31 mg, increase to 0.63 mg 3, 2
• Children with severe asthma demonstrate dose-response relationship favoring higher doses 2

Key Safety Considerations

Cardiovascular Effects:

• Levosalbutamol 0.31 mg is the only dose not significantly different from placebo for ventricular heart rate changes, QTc interval prolongation, and glucose elevation 2
• Racemic albuterol and levosalbutamol 0.63 mg both cause significant increases in heart rate, while 0.31 mg does not 3
• This is particularly important in very low birth weight infants where levosalbutamol 0.31 mg shows better hemodynamic stability 4

Metabolic Effects:

• All active doses decrease serum potassium (range -0.3 to -0.6 mEq/L) 2
• Beta-mediated side effects (tachycardia, tremor, hypokalemia) are dose-dependent 5

Delivery Method

For children <4 years:

• Use nebulizer with face mask and valved holding chamber 1
• Children this age have difficulty with MDI devices and may not generate sufficient inspiratory flow 1

Critical Pitfalls to Avoid

1. Do not use fixed adult dosing in young children - Weight-based dosing is safer in acute settings
2. Do not assume all children need 0.63 mg or higher - Starting with 0.31 mg provides excellent bronchodilation with minimal cardiovascular effects in most children with mild-moderate disease 2
3. Do not overlook the subset with severe asthma - These children may require the higher 0.63 mg or 1.25 mg doses for adequate response 2
4. Avoid mixing levosalbutamol with medications other than budesonide - Compatibility data is limited 1

Comparative Context

Levosalbutamol provides clinically comparable efficacy to 4- to 8-fold higher doses of racemic albuterol with a more favorable safety profile 2. The 0.31 mg dose of levosalbutamol produces similar FEV₁ improvements as racemic albuterol 1.25 mg, while the 0.63 mg dose matches racemic albuterol 2.5 mg 1, 5.